Cell-Type-Resolved Mendelian Randomization, Colocalization and Druggability of Asthma Using Single-Cell Immune eQTL.
Abstract
Objectives: Genome-wide association studies (GWAS) have identified over 212 asthma susceptibility loci, yet the effector genes and the immune cell subsets remain largely unresolved, because conventional prioritization relies on bulk-tissue expression quantitative trait loci (eQTL) that cannot resolve cellular heterogeneity. We aimed to build a cell-type-resolved map of candidate causal genes and prioritize druggable asthma targets. Methods: We integrated single-cell cis-eQTL across 20 peripheral-blood immune subsets from OneK1K with a European-ancestry asthma GWAS meta-analysis from the Global Biobank Meta-analysis Initiative (121,940 cases, 1,254,131 controls), using summary-data-based Mendelian randomization (SMR) with heterogeneity in dependent instrument (HEIDI) filtering followed by Bayesian colocalization, and annotated dual-evidence genes for tractability with the Open Targets Platform. Results: Across 12,754 gene–cell-subset tests, 437 associations were significant (false discovery rate < 0.05, HEIDI pass), implicating 202 genes. Colocalization supported 102 associations across 46 dual-evidence genes. At 17q21, ORMDL3 colocalized in B cells and GSDMB in natural killer, CD8+ effector-memory T and naive B cells. The IL18R1 signal (2q12) did not colocalize, consistent with linkage disequilibrium. In independent eQTL data, 18 of the 46 replicated in at least one pre-specified endpoint, including 10 in whole blood against one of 202 control genes, while the other 28 remain candidates. Twenty-three of the 46 carried tractability evidence, three at a clinical stage. Conclusions: Single-cell eQTL-based Mendelian randomization refines understanding of asthma genetic architecture and delivers a cell-type-anchored shortlist of candidate therapeutic targets. This two-pillar, cell-type-resolved framework yields testable mechanistic insights and supports translational development of precision therapeutic strategies for asthma.